Cholesterol Biosynthesis Disorders and Associated Metabolic Phenotypes

Cholesterol biosynthesis disorders encompass a group of inborn errors and pharmacologically induced perturbations affecting the multistep metabolic cascade that generates cholesterol from acetyl-CoA. Defects in key enzymes such as 7-dehydrocholesterol reductase (DHCR7), lathosterol 5-desaturase (SC5D) and sterol-C4-methyl oxidase manifest in syndromes including Smith-Lemli-Opitz, lathosterolosis and desmosterolosis. The resulting imbalance between cholesterol and precursor sterols disrupts membrane integrity, impairs Hedgehog signalling during embryogenesis and alters neurosteroid synthesis, giving rise to variable malformations, neurocognitive deficits and metabolic sequelae. Beyond genetic disorders, numerous commonly used drugs and environmental chemicals inhibit post-lanosterol enzymes, raising concerns about teratogenicity and long-term cardiovascular and neurodevelopmental risks. Clinical phenotypes range from growth retardation, limb and craniofacial anomalies, to behavioural disturbances and autism-like traits. Recent advances in mass spectrometry, oxysterol biomarker discovery and proteomics have elucidated the pathophysiological roles of accumulating sterol intermediates and non-sterol isoprenoids, highlighting potential therapeutic targets. Understanding the interplay between genetic mutations, environmental inhibitors and downstream metabolic pathways is critical for the development of precision diagnostics, risk-stratified pharmacovigilance and mechanism-based interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cholesterol Biosynthesis Disorders and Associated Metabolic Phenotypes publication trend

The graph below shows the total number of articles in cholesterol biosynthesis disorders and associated metabolic phenotypes across all publications each year (not limited to Nature Index journals).

Technical terms

7-Dehydrocholesterol (7-DHC): Immediate precursor to cholesterol in the Kandutsch–Russell pathway, accumulating in DHCR7 deficiency.

Oxysterols: Oxygenated derivatives of cholesterol or its precursors that serve as bioactive signalling molecules and biomarkers of oxidative stress.

DHCR7: 7-Dehydrocholesterol reductase, the enzyme catalysing the terminal step of cholesterol biosynthesis; mutations underlie Smith-Lemli-Opitz syndrome.

Hedgehog signalling: A morphogen pathway requiring cholesterol modification for ligand maturation, essential for embryonic patterning.

Bloch hypothesis: The proposition that each intermediate in the cholesterol biosynthetic pathway progressively enhances membrane stability and function in higher eukaryotes.

Isoprenoids: Non-sterol metabolites derived from the mevalonate pathway, involved in protein prenylation and intracellular trafficking.

References

1. Chemical Inhibition of Sterol Biosynthesis. Biomolecules (2024).
2. Smith-Lemli-Opitz syndrome: A pathophysiological manifestation of the Bloch hypothesis. Frontiers in Molecular Biosciences (2023).
3. Malformation syndromes caused by disorders of cholesterol synthesis. Journal of Lipid Research (2010).
4. An oxysterol biomarker for 7-dehydrocholesterol oxidation in cell/mouse models for Smith-Lemli-Opitz syndrome[S]. Journal of Lipid Research (2011).
5. Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update. Journal of Neurodevelopmental Disorders (2016).
6. Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol. Journal of Lipid Research (2018).
7. Quantitative Proteomics Analysis of Inborn Errors of Cholesterol Synthesis Identification of Altered Metabolic Pathways in DHCR7 and SC5D Deficiency*. Molecular & Cellular Proteomics (2010).